We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




New Blood Test Identifies People at Risk of Developing Blood Cancers

By LabMedica International staff writers
Posted on 28 Aug 2023
Print article
Image: The tool can identify individuals at risk of developing different myeloid leukaemias (Photo courtesy of 123RF)
Image: The tool can identify individuals at risk of developing different myeloid leukaemias (Photo courtesy of 123RF)

The myeloid neoplasms form a group of interconnected cancers encompassing acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Although treatments for these cancers have advanced in recent years, the majority of cases remain without a cure. Recent scientific discoveries have revealed that these cancers develop slowly over decades through the accumulation of DNA mutations in blood stem cells, which are responsible for normal blood formation. These mutations prompt these stem cells to grow faster than usual, and as additional mutations gather, they can lead to leukemia. Fortunately, while mutations promoting cell growth are prevalent, only a small subset of cases progresses to leukemia. Detecting these cases at an early stage could be vital in preventing the development of these cancers. Scientists have now developed a novel test to identify individuals at risk of developing acute myeloid leukemia and related cancers, years before their onset.

Researchers at the University of Cambridge (Cambridge, UK) along with their colleagues have introduced a new platform named 'MN-predict.' This platform empowers doctors and researchers to identify individuals at risk and devise new treatments to prevent the emergence of these potentially life-threatening cancers. The team examined data from over 400,000 individuals to create "MN-predict," a predictive tool capable of assessing the likelihood of developing blood cancers within a 10-15-year timeframe. This test involves patients providing a blood sample from which DNA is extracted and sequenced on a limited scale, along with basic blood cell counts. Armed with this information, the platform identifies those with a high risk of developing any of these cancers. Its application can be integrated into specialized clinics dedicated to leukemia prevention.

“We all know that prevention is better than cure, but it is not easy to prevent diseases like leukemia without knowing who is at risk,” said Professor George Vassiliou, senior author of the study. “MN-predict makes it possible to identify at-risk individuals, and we hope it can become an essential part of future leukemia prevention programs.”

Related Links:
University of Cambridge

New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
PoC Testing Device
QuikRead
New
DNA topoisomerase I ELISA
Anti-Scl-70 ELISA Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Immunology

view channel
Image: Bone marrow affected by multiple myeloma, a disease against which PVR inhibition can increase the efficacy of immunotherapy (Photo courtesy of Cancer Epigenetics Group, IJC)

Epigenetic Test Could Determine Efficacy of New Immunotherapy Treatments Against Multiple Myeloma

Multiple myeloma is a blood cancer that primarily affects individuals over the age of sixty, and its occurrence rises as the population ages. In this disease, the bone marrow—the spongy tissue inside bones... Read more

Microbiology

view channel
Image: New research promises a potential non-invasive stool test and novel therapy for endometriosis (Photo courtesy of Shutterstock)

Non-Invasive Stool Test to Diagnose Endometriosis and Help Reduce Disease Progression

Endometriosis, a painful condition impacting nearly 200 million women globally, occurs when tissue similar to the lining of the uterus grows outside its usual location, such as on the intestines or the... Read more

Pathology

view channel
Image: A glioblastoma tumor cell (green) present in the white matter (blue) near a blood vessel (red), visualized via the novel three-photon microscopy workflow Deep3P (Photo courtesy of EMBL/Heidelberg University)

Pioneering Microscopy Technique Improves Diagnosis of Glioblastoma Brain Tumors

Along the brain’s largest nerve fiber highway, known as the corpus callosum, travel cells that form one of the most lethal brain cancers, glioblastomas. Now, scientists have developed a cellular detector... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.